EXHIBIT 99.1 Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates $121.1 Million In Cash and Cash Equivalents at December 31, 2023, With an Additional$21.8 Million Raised In 2024 From Exercise of Warrants. A Total of Over 555 Study Participants Have Completed Our Phase 3 Studies. Topline Data Readout for Our 52-Week Phase 3 Trial Expected Year-End 2024. Internal Investigation by Outside Counsel Has Found No Evidence to Substantiate Allegations of Research Misconduct by the Compan ...